Literature DB >> 21204807

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Nahoko Kaniwa1, Yoshiro Saito, Michiko Aihara, Kayoko Matsunaga, Masahiro Tohkin, Kouichi Kurose, Hirokazu Furuya, Yukitoshi Takahashi, Masaaki Muramatsu, Shigeru Kinoshita, Masamichi Abe, Hiroko Ikeda, Mariko Kashiwagi, Yixuan Song, Mayumi Ueta, Chie Sotozono, Zenro Ikezawa, Ryuichi Hasegawa.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Recently, strong associations of HLA-B*1502 with carbamazepine-induced SJS/TEN have been found in Han Chinese patients. These associations have been confirmed in several Asian populations, excluding Japanese. SJS patients carrying HLA-B*1508, HLA-B*1511, or HLA-B*1521, which are members of the HLA-B75 type along with HLA-B*1502, were detected in studies in India and Thailand. In the current study, we genotyped the HLA-B locus from 14 Japanese typical and atypical SJS/TEN patients in whom carbamazepine was considered to be involved in the onset of adverse reactions. Although there were no HLA-B*1502 carriers, four patients had HLA-B*1511. Our data suggest that HLA-B*1511, a member of HLA-B75, is a risk factor for carbamazepine-induced SJS/TEN in Japanese. Wiley Periodicals, Inc.
© 2010 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21204807     DOI: 10.1111/j.1528-1167.2010.02766.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  57 in total

Review 1.  Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.

Authors:  Shareefa Dalvie; Nastassja Koen; Nathaniel McGregor; Kevin O'Connell; Louise Warnich; Raj Ramesar; Caroline M Nievergelt; Dan J Stein
Journal:  OMICS       Date:  2016-09-16

Review 2.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 3.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 4.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

Review 5.  The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review.

Authors:  Nahoko Kaniwa; Yoshiro Saito
Journal:  Ther Adv Drug Saf       Date:  2013-12

6.  Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.

Authors:  Rosa Chan; Chun-Yu Wei; Yuan-Tsong Chen; Leslie Z Benet
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

7.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 8.  A review of pharmacogenetics of adverse drug reactions in elderly people.

Authors:  Maurizio Cardelli; Francesca Marchegiani; Andrea Corsonello; Fabrizia Lattanzio; Mauro Provinciali
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

9.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 10.  Genotyping for severe drug hypersensitivity.

Authors:  Eric Karlin; Elizabeth Phillips
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.